Compound ID | 1841
Class: Aminoglycoside
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive, Gram-negative & Antimycobacterial |
| Mechanism of action: | Protein synthesis inhibitor. Binds to the bacterial 30S ribosomal subunit |
| Target Pathogen: | Broad spectrum activity including against Mycobacterium tuberculosis |
| Description: | Semisynthetic, derived from kanamycin. Veterinary use, human use as parenterial and inhaled formulation (for Mycobacterium avium complex lung disease) |
| Year first mentioned: | 1976 |
| Highest development stage: | Approved by FDA in 1981 |
| Development status: | Approved |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/37768 |
| Guide to Pharmacology: | amikacin |
| Citations: |
|